Denali Therapeutics Inc
NASDAQ:DNLI
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
14.96
31.58
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one DNLI stock under the Base Case scenario is 16.898 USD. Compared to the current market price of 28.835 USD, Denali Therapeutics Inc is Overvalued by 41%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Denali Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for DNLI cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Denali Therapeutics Inc
Balance Sheet Decomposition
Denali Therapeutics Inc
Current Assets | 868.8m |
Cash & Short-Term Investments | 836.6m |
Other Current Assets | 32.3m |
Non-Current Assets | 585.2m |
Long-Term Investments | 445.5m |
PP&E | 113.2m |
Other Non-Current Assets | 26.5m |
Current Liabilities | 87.1m |
Accounts Payable | 9.6m |
Accrued Liabilities | 61.2m |
Other Current Liabilities | 16.3m |
Non-Current Liabilities | 48.4m |
Long-Term Debt | 5.6m |
Other Non-Current Liabilities | 42.8m |
Earnings Waterfall
Denali Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-504.6m
USD
|
Operating Income
|
-504.6m
USD
|
Other Expenses
|
77.1m
USD
|
Net Income
|
-427.5m
USD
|
Free Cash Flow Analysis
Denali Therapeutics Inc
USD | |
Free Cash Flow | USD |
DNLI Profitability Score
Profitability Due Diligence
Denali Therapeutics Inc's profitability score is 13/100. The higher the profitability score, the more profitable the company is.
Score
Denali Therapeutics Inc's profitability score is 13/100. The higher the profitability score, the more profitable the company is.
DNLI Solvency Score
Solvency Due Diligence
Denali Therapeutics Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Denali Therapeutics Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DNLI Price Targets Summary
Denali Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for DNLI is 41.585 USD with a low forecast of 22.22 USD and a high forecast of 94.5 USD.
Dividends
Current shareholder yield for DNLI is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
DNLI Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. The company is headquartered in South San Francisco, California and currently employs 380 full-time employees. The company went IPO on 2017-12-08. The firm is focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and others. The firm clinical programs include leucine-rich repeat kinase 2 (LRRK2) inhibitor program, eukaryotic initiation factor 2 B (EIF2B) activator program, enzyme transport vehicle: iduronate 2-sulfatase (ETV:IDS) program, receptor interacting serine/threonine protein kinase 1 (RIPK1) inhibitor program and second non-CNS penetrant RIPK1 inhibitor. The firm engineers its product candidates to cross the blood-brain barrier (BBB), and act directly in the brain. Its pipeline includes approximately 15 programs that are based on its TV technology, including the lead program ETV:IDS (DNL310). Its product pipeline includes DNL151, DNL593 (PTV:PGRN), DNL126 (ETV:SGSH), DNL919 (ATV:TREM2), DNL788, DNL343, DNL758 and others.
Contact
IPO
Employees
Officers
The intrinsic value of one DNLI stock under the Base Case scenario is 16.898 USD.
Compared to the current market price of 28.835 USD, Denali Therapeutics Inc is Overvalued by 41%.